<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36739549</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1788-6120</ISSN><JournalIssue CitedMedium="Internet"><Volume>164</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>Orvosi hetilap</Title><ISOAbbreviation>Orv Hetil</ISOAbbreviation></Journal><ArticleTitle>[Characteristics of the course of lupus erythematosus panniculitis in a retrospective analysis of 17 patients].</ArticleTitle><Pagination><StartPage>172</StartPage><EndPage>178</EndPage><MedlinePgn>172-178</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1556/650.2023.32692</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Lupus erythematous panniculitis (LEP) is a rare type of chronic cutaneous lupus erythematous. Clinical characteristics are tender, subcutaneous nodules, erythematous plaques. Disfigurement of face and body might develop which affects the patient's quality of life. LEP can be the first sign of systemic lupus erythematous (SLE).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our aim was to review the clinicopathological characteristics and the course of LEP through our own patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed the clinical records of 17 LEP patients at Semmelweis University's Department of Dermatology, Venerology and Dermatooncology between 2000 and 2022.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The male&#xa0;:&#xa0;female ratio was 1&#xa0;:&#xa0;16, average age was 37.8 years. Lesion localisations were proximal lower (8/17) and upper extremities (7/17), face (4/17), breast (3/17), chest (2/17), buttocks (2/17), back (1/17) and distal lower extremity (1/17). Lesion morphologies were nodules (11/17), plaques (7/17), lipoatrophy (4/17), ulceration (3/17), calcification (1/17). Discoid changes covered in 6 cases. In 10 cases, systemic symptoms were observed (arthritis (4/17), haematological (5/17), renal (2/17), anti-phospholipid syndrome (2/17). 7 patients fulfilled the EULAR/ACR criteria for SLE. Histology showed mixed type panniculitis in 8, lobular in 3 cases. Average time until diagnosis was 24.3 months. Among all our SLE patients, skin symptoms regressed following systemic immunosuppressive treatment. LEP patients with only skin manifestation were often resistant for the therapy of cutaneous lupus erythematous.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The diagnosis of LEP often takes months or years. Wider knowledge of LEP would shorten the time to diagnosis, preventing disfigurement and possible damage of internal organs. Based on our observations, LEP without SLE might be treated with early immunosuppression. Orv Hetil. 2023; 164(5): 172-178.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kir&#xe1;ly</LastName><ForeName>Zs&#xf3;fia</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>1 Semmelweis Egyetem, &#xc1;ltal&#xe1;nos Orvostudom&#xe1;nyi Kar, B&#x151;r-, Nemik&#xf3;rtani &#xe9;s B&#x151;ronkol&#xf3;giai Klinika Budapest, M&#xe1;ria u. 41., 1085 Magyarorsz&#xe1;g.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kov&#xe1;cs</LastName><ForeName>Anik&#xf3;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1 Semmelweis Egyetem, &#xc1;ltal&#xe1;nos Orvostudom&#xe1;nyi Kar, B&#x151;r-, Nemik&#xf3;rtani &#xe9;s B&#x151;ronkol&#xf3;giai Klinika Budapest, M&#xe1;ria u. 41., 1085 Magyarorsz&#xe1;g.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medvecz</LastName><ForeName>M&#xe1;rta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 Semmelweis Egyetem, &#xc1;ltal&#xe1;nos Orvostudom&#xe1;nyi Kar, B&#x151;r-, Nemik&#xf3;rtani &#xe9;s B&#x151;ronkol&#xf3;giai Klinika Budapest, M&#xe1;ria u. 41., 1085 Magyarorsz&#xe1;g.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xf3;bert</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1 Semmelweis Egyetem, &#xc1;ltal&#xe1;nos Orvostudom&#xe1;nyi Kar, B&#x151;r-, Nemik&#xf3;rtani &#xe9;s B&#x151;ronkol&#xf3;giai Klinika Budapest, M&#xe1;ria u. 41., 1085 Magyarorsz&#xe1;g.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bokor</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1 Semmelweis Egyetem, &#xc1;ltal&#xe1;nos Orvostudom&#xe1;nyi Kar, B&#x151;r-, Nemik&#xf3;rtani &#xe9;s B&#x151;ronkol&#xf3;giai Klinika Budapest, M&#xe1;ria u. 41., 1085 Magyarorsz&#xe1;g.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuroli</LastName><ForeName>Enik&#x151;</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1 Semmelweis Egyetem, &#xc1;ltal&#xe1;nos Orvostudom&#xe1;nyi Kar, B&#x151;r-, Nemik&#xf3;rtani &#xe9;s B&#x151;ronkol&#xf3;giai Klinika Budapest, M&#xe1;ria u. 41., 1085 Magyarorsz&#xe1;g.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 Semmelweis Egyetem, &#xc1;ltal&#xe1;nos Orvostudom&#xe1;nyi Kar, Patol&#xf3;giai &#xe9;s K&#xed;s&#xe9;rleti R&#xe1;kkutat&#xf3; Int&#xe9;zet Budapest Magyarorsz&#xe1;g.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szepesi</LastName><ForeName>&#xc1;gota</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>2 Semmelweis Egyetem, &#xc1;ltal&#xe1;nos Orvostudom&#xe1;nyi Kar, Patol&#xf3;giai &#xe9;s K&#xed;s&#xe9;rleti R&#xe1;kkutat&#xf3; Int&#xe9;zet Budapest Magyarorsz&#xe1;g.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marschalk&#xf3;</LastName><ForeName>M&#xe1;rta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 Semmelweis Egyetem, &#xc1;ltal&#xe1;nos Orvostudom&#xe1;nyi Kar, B&#x151;r-, Nemik&#xf3;rtani &#xe9;s B&#x151;ronkol&#xf3;giai Klinika Budapest, M&#xe1;ria u. 41., 1085 Magyarorsz&#xe1;g.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidv&#xe9;gi</LastName><ForeName>Bernadett</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>1 Semmelweis Egyetem, &#xc1;ltal&#xe1;nos Orvostudom&#xe1;nyi Kar, B&#x151;r-, Nemik&#xf3;rtani &#xe9;s B&#x151;ronkol&#xf3;giai Klinika Budapest, M&#xe1;ria u. 41., 1085 Magyarorsz&#xe1;g.</Affiliation></AffiliationInfo></Author></AuthorList><Language>hun</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>A lupus erythematosus panniculitis lefoly&#xe1;s&#xe1;nak jellegzetess&#xe9;gei 17 beteg&#xfc;nk retrospekt&#xed;v vizsg&#xe1;lata alapj&#xe1;n.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Hungary</Country><MedlineTA>Orv Hetil</MedlineTA><NlmUniqueID>0376412</NlmUniqueID><ISSNLinking>0030-6002</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015435" MajorTopicYN="Y">Panniculitis, Lupus Erythematosus</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015434" MajorTopicYN="Y">Panniculitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="hun"><AbstractText>Bevezet&#xe9;s: A lupus erythematosus panniculitis (LEP) a cutan lupus erythematosus kr&#xf3;nikus form&#xe1;j&#xe1;nak ritka vari&#xe1;nsa, klinikailag t&#xf6;m&#xf6;tt, subcutan csom&#xf3;k &#xe9;s erythem&#xe1;s plakkok jellemzik. Az akt&#xed;v t&#xfc;netek az arcot &#xe9;s testet torz&#xed;t&#xf3; maradv&#xe1;nyt&#xfc;netekkel gy&#xf3;gyulhatnak, rontva a betegek &#xe9;letmin&#x151;s&#xe9;g&#xe9;t. A sziszt&#xe9;m&#xe1;s lupus erythematosus (SLE) r&#xe9;szjelens&#xe9;ge lehet, els&#x151; t&#xfc;netek&#xe9;nt is kialakulhat. C&#xe9;lkit&#x171;z&#xe9;s: A LEP klinikopatol&#xf3;giai k&#xe9;p&#xe9;nek bemutat&#xe1;sa saj&#xe1;t beteganyagunk szeml&#xe9;ltet&#xe9;s&#xe9;vel, a betegs&#xe9;g lefoly&#xe1;s&#xe1;nak &#xe9;rt&#xe9;kel&#xe9;se. M&#xf3;dszerek: A Semmelweis Egyetem B&#x151;r-, Nemik&#xf3;rtani &#xe9;s B&#x151;ronkol&#xf3;giai Klinik&#xe1;j&#xe1;n 2000 &#xe9;s 2022 k&#xf6;z&#xf6;tt jelentkezett LEP-betegek &#xf6;sszegy&#x171;jt&#xe9;se, adataik retrospekt&#xed;v elemz&#xe9;se. Eredm&#xe9;nyek: A 17 beteg k&#xf6;z&#xfc;l 1 f&#xe9;rfi, 16 n&#x151;, &#xe1;tlag&#xe9;letkoruk 37,8 &#xe9;v volt. T&#xfc;neteik a leggyakrabban a proximalis als&#xf3; &#xe9;s fels&#x151; v&#xe9;gtagokon jelentkeztek (als&#xf3;: 8/17, fels&#x151;: 7/17), az arc 4, az eml&#x151; 3, a mellkas &#xe9;s a farpof&#xe1;k 2-2, a h&#xe1;t &#xe9;s a l&#xe1;bsz&#xe1;r 1-1 esetben volt &#xe9;rintett. A leggyakrabban akt&#xed;v csom&#xf3; (11/17), illetve plakk jelentkezett (7/17), 4 esetben lipoatrophia, 3-n&#xe1;l kifek&#xe9;lyesed&#xe9;s, 1-n&#xe9;l kalcifik&#xe1;ci&#xf3;. 6 betegn&#xe9;l a subcutan t&#xfc;netet discoid plakk fedte. 10 betegn&#xe9;l alakult ki sziszt&#xe9;m&#xe1;s t&#xfc;net: arthritis (4/17), hematol&#xf3;giai elt&#xe9;r&#xe9;s (5/17), vese&#xe9;rintetts&#xe9;g (2/17), antifoszfolipid-szindr&#xf3;ma (2/17). Az SLE diagn&#xf3;zis&#xe1;t 7 esetben tudtuk fel&#xe1;ll&#xed;tani. A sz&#xf6;vettani k&#xe9;p 8 esetben kevert t&#xed;pus&#xfa; panniculitist, 3-n&#xe1;l lobularist mutatott. &#xc1;tlagosan 24,3 h&#xf3;nap telt el a diagn&#xf3;zis fel&#xe1;ll&#xed;t&#xe1;s&#xe1;ig. SLE-s betegeink b&#x151;rt&#xfc;netei regredi&#xe1;ltak az alkalmazott sziszt&#xe9;m&#xe1;s immunszuppressz&#xed;v kezel&#xe9;sekre. A kiz&#xe1;r&#xf3;lag b&#x151;rmanifeszt&#xe1;ci&#xf3;t mutat&#xf3; betegeink k&#xf6;r&#xe9;ben gyakori volt a ter&#xe1;piarezisztencia a cutan lupus erythematosusban alkalmazott kezel&#xe9;sekre. K&#xf6;vetkeztet&#xe9;s: A LEP diagnosztiz&#xe1;l&#xe1;sa t&#xf6;bb h&#xf3;napot, &#xe9;vet vehet ig&#xe9;nybe. Sz&#xe9;lesebb k&#xf6;r&#x171; ismerete seg&#xed;theti a gyorsabb diagn&#xf3;zisalkot&#xe1;st, megel&#x151;zhet&#x151; a maradv&#xe1;nyt&#xfc;netek, illetve az esetleges belszervi elv&#xe1;ltoz&#xe1;sok kialakul&#xe1;sa. Megfigyel&#xe9;seink alapj&#xe1;n SLE n&#xe9;lk&#xfc;li LEP eset&#xe9;n is korai immunszuppressz&#xed;v ter&#xe1;pi&#xe1;t lenne &#xe9;rdemes bevezetni. Orv Hetil. 2023; 164(5): 172&#x2013;178.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">lupus erythematosus panniculitis</Keyword><Keyword MajorTopicYN="N">lupus erythematosus profundus</Keyword><Keyword MajorTopicYN="N">lupus erythematous panniculitis</Keyword><Keyword MajorTopicYN="N">mastitis</Keyword><Keyword MajorTopicYN="N">panniculitis</Keyword><Keyword MajorTopicYN="N">profound lupus erythematous</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematous</Keyword><Keyword MajorTopicYN="N">sziszt&#xe9;m&#xe1;s lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>5</Day><Hour>14</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36739549</ArticleId><ArticleId IdType="doi">10.1556/650.2023.32692</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>